دورية أكاديمية
أعرض في EDS

Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.

التفاصيل البيبلوغرافية
العنوان: Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.
المؤلفون: Chiong E; Department of Urology, National University Hospital, Department of Surgery, National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Singapore., Saad M; Clinical Oncology Unit, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Hamid ARAH; Department of Urology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Indonesia., Ong-Cornel AB; Section of Oncology, Veteran's Memorial Medical Center, Quezon City, Philippines., Lojanapiwat B; Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai, Thailand., Pripatnanont C; Genitourinary Surgery, Chulabhorn Hospital, Bangkok, Thailand., Serrano D; Division of Urology, Department of Surgery, University of the Philippines College of Medicine - Philippines General Hospital, Manila, Philippines., Songco J; Department of Urology, Cancer Center, Makati Medical Center, Manila, Philippines., Sin LC; Department of Urology, Department of Surgery, Gleneagles Hospital, Kuala Lumpur, Malaysia., Hakim L; Department of Urology, Faculty of Medicine, Airlangga University/Airlangga University Teaching Hospital, Surabaya, East Java, Indonesia., Chua MLK; Division of Radiation Oncology, National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore., Nguyen NP; Department of Oncology, Binh Dan Hospital, Ho Chi Minh City, Vietnam., Phuong PC; The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam., Patnaik RS; Department of Oncology, The Brunei Cancer Centre (TBCC), Pantai Jerudong Specialist Centre, Jerudong, Brunei., Umbas R; Department of Urology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Indonesia., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
المصدر: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Jan 18; Vol. 16, pp. 17588359231216582. Date of Electronic Publication: 2024 Jan 18 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Sage
مستخلص: Background: Prostate cancer (PC) has a serious public health impact, and its incidence is rising due to the aging population. There is limited evidence and consensus to guide the management of PC in Southeast Asia (SEA). We present real-world data on clinical practice patterns in SEA for advanced PC care.
Method: A paper-based survey was used to identify clinical practice patterns and obtain consensus among the panelists. The survey included the demographics of the panelists, the use of clinical guidelines, and clinical practice patterns in the management of advanced PC in SEA.
Results: Most panelists (81%) voted prostate-specific antigen (PSA) as the most effective test for early PC diagnosis and risk stratification. Nearly 44% of panelists agreed that prostate-specific membrane antigen positron emission tomography-computed tomography imaging for PC diagnostic and staging information aids local and systemic therapy decisions. The majority of the panel preferred abiraterone acetate (67%) or docetaxel (44%) as first-line therapy for symptomatic mCRPC patients. Abiraterone acetate (50%) is preferred over docetaxel as a first-line treatment in metastatic castration-sensitive prostate cancer patients with high-volume disease. However, the panel did not support the use of abiraterone acetate in non-metastatic castration-resistant prostate cancer (nmCRPC) patients. Apalutamide (75%) is the preferred treatment option for patients with nmCRPC. The cost and availability of modern treatments and technologies are important factors influencing therapeutic decisions. All panelists supported the use of generic versions of approved therapies.
Conclusion: The survey results reflect real-world management of advanced PC in a SEA country. These findings could be used to guide local clinical practices and highlight the financial challenges of modern healthcare.
Competing Interests: The authors declare that there is no conflict of interest.
(© The Author(s), 2024.)
References: Lancet. 2010 Oct 2;376(9747):1186-93. (PMID: 20709386)
Eur Urol. 2008 Oct;54(4):942-3. (PMID: 18953753)
JAMA Netw Open. 2022 Mar 1;5(3):e222246. (PMID: 35285916)
BJU Int. 2019 Sep;124(3):373-382. (PMID: 31077523)
Clin Chem. 2021 Mar 31;67(4):602-609. (PMID: 33619518)
Eur Urol. 2013 Mar;63(3):583-4. (PMID: 23357896)
Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:12-26. (PMID: 33860645)
Ther Adv Urol. 2010 Apr;2(2):77-83. (PMID: 21789085)
Asian J Androl. 2015 May-Jun;17(3):475-80. (PMID: 25578935)
Front Oncol. 2022 Jul 18;12:962958. (PMID: 35924163)
Clin Chem Lab Med. 2023 Jan 27;61(7):1327-1334. (PMID: 36704961)
Cancers (Basel). 2021 Feb 01;13(3):. (PMID: 33535541)
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. (PMID: 33556313)
Prostate Int. 2015 Dec;3(4):135-40. (PMID: 26779461)
BJU Int. 2018 May;121 Suppl 3:22-27. (PMID: 29359883)
Chin J Cancer Res. 2019 Apr;31(2):259-277. (PMID: 31156298)
Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:39-47. (PMID: 33860642)
Lancet Oncol. 2015 Feb;16(2):152-60. (PMID: 25601341)
World J Oncol. 2019 Apr;10(2):63-89. (PMID: 31068988)
Ther Adv Med Oncol. 2022 Nov 14;14:17588359221131525. (PMID: 36407784)
Ann Acad Med Singap. 2015 Oct;44(10):397-405. (PMID: 26763057)
JCO Glob Oncol. 2020 Mar;6:382-386. (PMID: 32125899)
Medicine (Baltimore). 2020 Sep 25;99(39):e22336. (PMID: 32991446)
J Clin Oncol. 2018 May 10;36(14):1389-1395. (PMID: 29590007)
Lancet Oncol. 2015 May;16(5):509-21. (PMID: 25888263)
JAMA Netw Open. 2022 May 2;5(5):e2211869. (PMID: 35576008)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cancer Sci. 2021 Jun;112(6):2071-2080. (PMID: 33738901)
Int J Mol Sci. 2020 Feb 20;21(4):. (PMID: 32093338)
Asia Pac J Clin Oncol. 2018 Aug;14(4):347-352. (PMID: 29663669)
Prostate Int. 2019 Sep;7(3):108-113. (PMID: 31485435)
Lancet. 2011 Jan 29;377(9763):429-37. (PMID: 21269685)
Int J Urol. 2017 Sep;24(9):648-666. (PMID: 28667698)
Lancet Oncol. 2013 Nov;14(12):e524-34. (PMID: 24176571)
J Urol. 2021 Jan;205(1):14-21. (PMID: 32960679)
Nat Rev Urol. 2021 May;18(5):282-301. (PMID: 33692499)
Front Oncol. 2021 Apr 13;11:646073. (PMID: 33928035)
ESMO Open. 2022 Aug;7(4):100518. (PMID: 35797737)
فهرسة مساهمة: Keywords: abiraterone acetate; advanced prostate cancer; androgen deprivation; mCRPC; mCSPC; nmCRPC
تواريخ الأحداث: Date Created: 20240122 Latest Revision: 20240123
رمز التحديث: 20240123
مُعرف محوري في PubMed: PMC10798109
DOI: 10.1177/17588359231216582
PMID: 38249332
قاعدة البيانات: MEDLINE
الوصف
تدمد:1758-8340
DOI:10.1177/17588359231216582